Skip to main content
. Author manuscript; available in PMC: 2015 Aug 20.
Published in final edited form as: Cancer Biol Ther. 2009 Nov 27;8(22):2186–2193. doi: 10.4161/cbt.8.22.10446

Figure 1. Upregulation of p53-dependent transcriptional activity or endogenous pro-apoptotic TRAIL receptor DR5 expression following p53 pathway restoration.

Figure 1

In the upper panels, a whole population of Phoenix cells expressing a p53-responsive EGFP reporter show increased EGFP reporter expression following infection by a p73-expressing Adenovirus (upper right panel vs. upper left panel). In the lower panels, mutant p53-expressing human colon cancer DLD1 cells were treated with 15 μg/ml of the mutant p53 conformation modifying drug CP-31398 for 12 hours followed by fluorescence microscopy for p53 target TRAIL receptor DR5 expression by immunofluorescence with a DAPI nuclear counterstain. The lower left panel shows DR5 expression in untreated DLD1 cells and the lower right panel shows DR5 expression in CP-31398 treated DLD1 cells.